Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
September 10, 2024 08:00 ET
|
Belite Bio, Inc
Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent STGD1 subjects across the U.S., U.K., and JapanPhase 1b of DRAGON II...
Belite Bio 宣佈委任醫學博士Hendrik P. N. Scholl 為首席醫療總監
September 03, 2024 20:16 ET
|
Belite Bio, Inc
在眼科領域，Scholl 博士是全球公認的領軍人物，同時也在史上規模最大的斯特格病變自然病史研究中擔任協調首席研究員 聖地牙哥, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE)（以下簡稱「Belite Bio」或「公司」）Belite Bio...
Belite Bio 宣布任命 Hendrik P. N. Scholl 医学博士为首席医学官
September 03, 2024 20:16 ET
|
Belite Bio, Inc
Scholl 博士是全球眼科领域备受推崇的领军人物，并在规模最大的斯特格病自然病程研究中担任协调首席研究员 圣迭戈, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc（纳斯达克股票代码：BLTE）（以下简称“Belite...
ベライト・バイオ (Belite Bio)、ヘンドリック・P・N・ショル医学博士、修士 (Hendrik P. N. Scholl, MD, MA) をチーフ・メディカル・オフィサーに任命
September 03, 2024 19:00 ET
|
Belite Bio, Inc
ショル博士は眼科の分野で世界的に認められたリーダーであり、スターガルト病の史上最大規模の自然史研究の調整主任研究者 サンディエゴ発, Sept. 04, 2024 (GLOBE NEWSWIRE) -- アンメット・メディカル・ニーズの変性網膜疾患を対象とした新規治療薬の開発に注力する臨床段階のバイオ医薬品開発会社であるベライト・バイオ (Belite Bio, Inc) (NASDAQ:...
Belite Bio to Participate in Three Upcoming Investor Conferences
September 03, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio Mengumumkan Pelantikan Hendrik P. N. Scholl, MD, MA, sebagai Ketua Pegawai Perubatan
September 01, 2024 20:00 ET
|
Belite Bio, Inc
Dr. Scholl adalah pemimpin yang diiktiraf di peringkat global dalam bidang oftalmologi dan penyelidik utama penyelaras bagi kajian sejarah semula jadi terbesar bagi penyakit Stargardt. SAN DIEGO,,...
Belite Bio, 최고 의학 책임자로 Hendrik P. N. Scholl 박사 선임 발표
September 01, 2024 19:00 ET
|
Belite Bio, Inc
안과 분야에서 세계적으로 인정받는 권위자인 Scholl 박사는 스타가르트 질환 관련 사상 최대 규모의 자연사 연구 공동 책임 연구자로도 활동 중 샌디에고, Sept. 02, 2024 (GLOBE NEWSWIRE) -- 임상 단계 바이오 의약품 개발 기업인 벨라이트 바이오(Belite Bio, Inc)(나스닥: BLTE)(이하 '벨라이트 바이오'...
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
September 01, 2024 08:00 ET
|
Belite Bio, Inc
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. ...
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 09, 2024 16:30 ET
|
Belite Bio, Inc
Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular...
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...